Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment

Drug and Alcohol Dependence

Volumn 127, Issue 1-3, 2013, Pages 243-247

  Savant, Jonathan D ^b   Barry, Declan T ^a   Cutter, Christopher J ^a   Joy, Michelle T ^a   Dinh, An ^a   Schottenfeld, Richard S ^a   Fiellin, David A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b APT Foundation ^*  (United States)

Author keywords

Buprenorphine; Comorbidity; Diagnosis, Dual (psychiatry); Opioid related disorders; Primary health care; Substance related disorders

Indexed keywords

ALCOHOL; BUPRENORPHINE; CANNABIS; CENTRAL STIMULANT AGENT; COCAINE; NALOXONE; PSYCHEDELIC AGENT; SEDATIVE AGENT;

ADULT; ALCOHOLISM; ARTICLE; CANNABIS ADDICTION; COCAINE DEPENDENCE; COMORBIDITY; CROSS-SECTIONAL STUDY; DISEASE CLASSIFICATION; DYSTHYMIA; FEMALE; HEALTH SURVEY; HUMAN; HYPOMANIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MANIA; MOOD DISORDER; OPIATE ADDICTION; PATIENT ASSESSMENT; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; SUBSTANCE ABUSE;

ADOLESCENT; ADULT; BUPRENORPHINE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; NALOXONE; OPIOID-RELATED DISORDERS; PREVALENCE; PRIMARY HEALTH CARE; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

CANNABIS;

EID: 84870934837     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.06.020     Document Type: Article

References (51)

1. Alford D.P., LaBelle C.T., Kretsch N., Bergeron A., Winter M., Botticelli M., Samet J.H. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch. Intern. Med. 2011, 171:425-431.
2. Brooner R.K., King V.L., Kidorf M., Schmidt C.W., Bigelow G.E. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch. Gen. Psychiatry 1997, 54:71-80.
3. Bux D.A., Lamb R.J., Iguchi M.Y. Cocaine use and HIV risk behavior in methadone maintenance patients. Drug Alcohol Depend. 1995, 37:29-35.
4. Cacciola J.S., Alterman A.I., Rutherford M.J., McKay J.R., Mulvaney F.D. The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients. Drug Alcohol Depend. 2001, 61:271-280.
5. Carpentier P.J., Krabbe P.F.M., Van Gogh M.T., Knapen L.J.M., Buitelaar J.K., De Jong C.A.J. Psychiatric comorbidity reduces quality of life in chronic methadone maintained patients. Am. J. Addict. 2009, 18:470-480.
6. Compton W.M., Cottler L.B., Jacobs J.L., Ben-Abdallah A., Spitznagel E.L. The role of psychiatric disorders in predicting drug dependence treatment outcomes. Am. J. Psychiatry 2003, 160:890-895.
7. Compton W.M., Thomas Y.F., Stinson F.S., Grant B.F. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch. Gen. Psychiatry 2007, 64:566-576.
8. Darke S., Mills K., Teesson M., Ross J., Williamson A., Havard A. Patterns of major depression and drug-related problems amongst heroin users across 36 months. Psychiatry Res. 2009, 166:7-14.
9. Darke S., Ross J. Polydrug dependence and psychiatric comorbidity among heroin injectors. Drug Alcohol Depend. 1997, 48:135-141.
10. Darke S., Swift W., Hall W., Ross M. Drug use, HIV risk-taking and psychosocial correlates of benzodiazepine use among methadone maintenance clients. Drug Alcohol Depend. 1993, 34:67-70.
11. Darke S., Williamson A., Ross J., Teesson M. Attempted suicide among heroin users: 12-month outcomes from the Australian Treatment Outcome Study (ATOS). Drug Alcohol Depend. 2005, 78:177-186.
12. Dean A.J., Bell J., Christie M.J., Mattick R.P. Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence. Eur. Psychiatry 2004, 19:510-513.
13. el-Bassel N., Schilling R.F., Turnbull J.E., Su K.H. Correlates of alcohol use among methadone patients. Alcohol. Clin. Exp. Res. 1993, 17:681-686.
14. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P) 2002, Biometrics Research, New York State Psychiatric Institute, New York.
15. Gonzalez G., Feingold A., Oliveto A., Gonsai K., Kosten T.R. Comorbid major depressive disorder as a prognostic factor in cocaine-abusing buprenorphine-maintained patients treated with desipramine and contingency management. Am. J. Drug Alcohol Abuse 2003, 29:497-514.
16. Greene P. Outpatient Drug Utilization Trends for Buprenorphine Years 2002-2009 2010, (accessed 13.08.11). http://buprenorphine.samhsa.gov/meetings.html.
17. Grella C.E., Anglin M.D., Wugalter S.E. Cocaine and crack use and HIV risk behaviors among high-risk methadone maintenance clients. Drug Alcohol Depend. 1995, 37:15-21.
18. Grella C.E., Anglin M.D., Wugalter S.E. Patterns and predictors of cocaine and crack use by clients in standard and enhanced methadone maintenance treatment. Am. J. Drug Alcohol Abuse 1997, 23:15-42.
19. Hasin D.S., Goodwin R.D., Stinson F.S., Grant B.F. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch. Gen. Psychiatry 2005, 62:1097-1106.
20. Hasin D.S., Stinson F.S., Ogburn E., Grant B.F. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch. Gen. Psychiatry 2007, 64:830-842.
21. Havard A., Teesson M., Darke S., Ross J. Depression among heroin users: 12-month outcomes from the Australian Treatment Outcome Study (ATOS). J. Subst. Abuse Treat. 2006, 30:355-362.
22. Hesse M. The Beck Depression Inventory in patients undergoing opiate agonist maintenance treatment. Br. J. Clin. Psychol. 2006, 45:417-425.
23. Kidorf M., Brooner R.K., King V.L., Chutuape M.A., Stitzer M.L. Concurrent validity of cocaine and sedative dependence diagnoses in opioid-dependent outpatients. Drug Alcohol Depend. 1996, 42:117-123.
24. Kidorf M., Brooner R.K., King V.L., Stoller K.B., Wertz J. Predictive validity of cocaine, sedative, and alcohol dependence diagnoses. J. Consult. Clin. Psychol. 1998, 66:168-173.
25. Kidorf M., Disney E.R., King V.L., Neufeld K., Beilenson P.L., Brooner R.K. Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program. Drug Alcohol Depend. 2004, 74:115-122.
26. Kosten T., Oliveto A., Feingold A., Poling J., Sevarino K., McCance-Katz E., Stine S., Gonzalez G., Gonsai K. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend. 2003, 70:315-325.
27. Kosten T.R., Gawin F.H., Rounsaville B.J., Kleber H.D. Cocaine abuse among opioid addicts: demographic and diagnostic factors in treatment. Am. J. Drug Alcohol Abuse 1986, 12:1-16.
28. Kosten T.R., Rounsaville B.J., Kleber H.D. Antecedents and consequences of cocaine abuse among opioid addicts: a 2.5-year follow-up. J. Nerv. Ment. Dis. 1988, 176:176-181.
29. Magura S., Lee S.J., Salsitz E.A., Kolodny A., Whitley S.D., Taubes T., Seewald R., Joseph H., Kayman D.J., Fong C., Marsch L.A., Rosenblum A. Outcomes of buprenorphine maintenance in office-based practice. J. Addict. Dis. 2007, 26:13-23.
30. McKay J.R., Weiss R.V. A review of temporal effects and outcome predictors in substance abuse treatment studies with long-term follow-ups. Eval. Rev. 2001, 25:113-161.
31. Nunes E.V., Quitkin F.M., Donovan S.J., Deliyannides D., Ocepek-Welikson K., Koenig T., Brady R., McGrath P.J., Woody G. Imipramine treatment of opiate-dependent patients with depressive disorders: a placebo-controlled trial. Arch. Gen. Psychiatry 1998, 55:153-160.
32. Pani P.P., Maremmani I., Pacini M., Lamanna F., Maremmani A.G.I. Effect of psychiatric severity on the outcome of methadone maintenance treatment. Eur. Addict. Res. 2010, 17:80-89.
33. Parran T.V., Adelman C.A., Merkin B., Pagano M.E., Defranco R., Ionescu R.A., Mace A.G. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend. 2010, 106:56-60.
34. Preston K.L., Silverman K., Higgins S.T., Brooner R.K., Montoya I., Schuster C.R., Cone E.J. Cocaine use early in treatment predicts outcome in a behavioral treatment program. J. Consult. Clin. Psychol. 1998, 66:691-696.
35. Ross J., Teesson M., Darke S., Lynskey M. The characteristics of heroin users entering treatment: findings from the Australian Treatment Outcome Study (ATOS). Drug Alcohol Rev. 2005, 24:411-418.
36. Ross S. The mentally ill substance abuser. The American Psychiatric Publishing Textbook of Substance Abuse Treatment 2008, American Psychiatric Publication, Washington, DC. M. Galanter, H.D. Kleber (Eds.).
37. Rounsaville B.J., Kosten T.R., Weissman M.M., Kleber H.D. Prognostic significance of psychopathology in treated opiate addicts: a 2.5-year follow-up study. Arch. Gen. Psychiatry 1986, 43:739-745.
38. Rounsaville B.J., Weissman M.M., Crits-Christoph K., Wilber C., Kleber H. Diagnosis and symptoms of depression in opiate addicts: course and relationship to treatment outcome. Arch. Gen. Psychiatry 1982, 39:151-156.
39. Rounsaville B.J., Weissman M.M., Kleber H., Wilber C. Heterogeneity of psychiatric diagnosis in treated opiate addicts. Arch. Gen. Psychiatry 1982, 39:161-166.
40. Schäfer I., Fischer M., Reimer J., Karow A., Haasen C. Significance of psychiatric comorbidity for the outcome of maintenance treatment - a review of the literature. Ment. Health Subst. Use 2011, 4:62-71.
41. Soeffing J.M., Martin L.D., Fingerhood M.I., Jasinski D.R., Rastegar D.A. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J. Subst. Abuse Treat. 2009, 37:426-430.
42. Srivastava A., Kahan M., Ross S. The effect of methadone maintenance treatment on alcohol consumption: a systematic review. J. Subst. Abuse Treat. 2008, 34:215-223.
43. Stein M.D., Cioe P., Friedmann P.D. Buprenorphine retention in primary care. J. Gen. Intern. Med. 2005, 20:1038-1041.
44. Stein M.D., Herman D.S., Kettavong M., Cioe P.A., Friedmann P.D., Tellioglu T., Anderson B.J. Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons. J. Subst. Abuse Treat. 2010, 39:157-166.
45. Stein M.D., Solomon D.A., Herman D.S., Anthony J.L., Ramsey S.E., Anderson B.J., Miller I.W. Pharmacotherapy plus psychotherapy for treatment of depression in active injection drug users. Arch. Gen. Psychiatry 2004, 61:152-159.
46. Stenbacka M., Beck O., Leifman A., Romelsjö A., Helander A. Problem drinking in relation to treatment outcome among opiate addicts in methadone maintenance treatment. Drug Alcohol Rev. 2007, 26:55-63.
47. Strain E.C. Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients. Clin. J. Pain 2002, 18:S14-S27.
48. Sullivan L.E., Chawarski M., O'Connor P.G., Schottenfeld R.S., Fiellin D.A. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?. Drug Alcohol Depend. 2005, 79:113-116.
49. Sullivan L.E., Moore B.A., O'Connor P.G., Barry D.T., Chawarski M.C., Schottenfeld R.S., Fiellin D.A. The association between cocaine use and treatment outcomes in patients receiving office based buprenorphine/naloxone for the treatment of opioid dependence. Am. J. Addict. 2010, 19:53-58.
50. Torrens M., Martínez-Sanvisens D., Martínez-Riera R., Bulbena A., Szerman N., Ruiz P. Dual diagnosis: focusing on depression and recommendations for treatment. Addict. Disord. Their Treat. 2011, 10:50-59.
51. Tzilos G.K., Rhodes G.L., Ledgerwood D.M., Greenwald M.K. Predicting cocaine group treatment outcome in cocaine-abusing methadone patients. Exp. Clin. Psychopharmacol. 2009, 17:320-325.